Wooree Group presented six steps: Cryo-TEM structure verification; NTA size, distribution and concentration; encapsulation efficiency; shelf stability; gastrointestinal stability; and pharmacokinetic assessment.

The due-diligence principle is sound: phospholipids, small particles or a process claim do not by themselves establish formation, stability and biological performance of a liposomal system.

The framework remains a company proposal and the proposer markets liposomal ingredients. Adoption requires validated methods, acceptance criteria, reproducibility and independent comparison.

Why it matters

Delivery technology and bioavailability are becoming B2B differentiators; value will depend on methods and data, not the label alone.

Evidence limit

A company proposal linked to a commercial portfolio: it is not a regulation, consensus standard or independent validation of the proposer’s products.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · Wooree Group ↗